Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  iodine I 131
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-14 of 14 for your search:
Start Over
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: rAd-p53-003, NCT00902122
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UCL/10/0299, 2011-000144-21, Cancer Research UK, ISRCTN, NCT01398085
Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: NCCCTS13-671, 1410650-1,2, NCT02418247
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Estimabl, CSET 1216, NCT00435851
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-A01569-34, 2012/1913, NCT01837745
Radioactive Iodide Therapy for Pediatric Graves' Disease
Phase: Phase II
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: 0904005064, 1R01FD003707, NCT01269749
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01106, 13-157, 9446, P30CA008748, NCT02152995
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RU241306I, NCI-2015-00277, P30CA015083, NCT02393690
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC0252, P30CA015083, 06-009392, NCI-2009-01195, MAYO-MC0252, NCT00788307
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
Phase: No phase specified
Type: Diagnostic
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CCR3047, NCT00749697
Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-292, NCT00926978
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DOSIMETA IGR2010/1645, NCT01403324
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: UKW-NUK-I-124, NCT01704586
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-031, NCT02145143
Start Over